Burow Kristina — SEC insider filings
SEC reporting owner CIK 1569248. 65 insider filings on record with FilingPulse; latest filed 2026-11-05.
Transaction summary — filings shown
Covers the 50 most recent of 65 filings on record, filed 2021-08-09 to 2026-11-05. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 39 legs across 20 filings — 21,856,152 shares, $233,589,954 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 5 legs across 3 filings — 24,453 shares, $364,414 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 123.
- Largest priced transaction: purchase of 1,432,224 shares @ $18.00 ($25,780,032) in Metsera, Inc., filed 2025-02-03.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Prime Medicine, Inc. (PRME) | 10% owner | 3 | 4 legs · 7,030,300 sh · $43,599,990 | — | 6 |
| Metsera, Inc. (MTSR) | Director | 3 | 2 legs · 2,222,222 sh · $39,999,996 | — | 16 |
| Lyell Immunopharma, Inc. (LYEL) | 10% owner | 2 | 2 legs · 2,809,352 sh · $37,499,977 | — | — |
| Neumora Therapeutics, Inc. (NMRA) | Director, 10% owner | 14 | 20 legs · 3,922,764 sh · $36,430,001 | — | 28 |
| Kardigan, Inc. (KARD) | Director, 10% owner | 2 | 1 leg · 1,250,000 sh · $20,000,000 | — | 4 |
| Aspen Neuroscience, Inc. (ASPE) | 10% owner | 2 | 3 legs · 1,333,333 sh · $19,999,995 | — | 18 |
| Seaport Therapeutics, Inc. (SPTX) | 10% owner | 1 | 1 leg · 1,100,000 sh · $19,800,000 | — | 4 |
| Sana Biotechnology, Inc. (SANA) | 10% owner | 1 | 3 legs · 1,818,181 sh · $9,999,996 | — | — |
| Boundless Bio, Inc. (BOLD) | 10% owner | 4 | 2 legs · 200,000 sh · $3,200,000 | 1 leg · 16,000 sh · $39,840 | 14 |
| CITY THERAPEUTICS, INC. (CTY) | 10% owner | 2 | 1 leg · 170,000 sh · $3,060,000 | — | 6 |
+5 more issuers among the filings shown — every filing appears in the table below.
Insider filings — Burow Kristina
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-05 | 4 | Lyell Immunopharma, Inc. (LYEL) jointly with ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, CRANDELL KEITH, GILLIS STEVEN, NELSEN ROBERT, BERNS PAUL L, BYBEE CLINTON | Purchase (P): 2,321,262 @ $10.77 | EDGAR |
| 2026-11-02 | 4 | Aspen Neuroscience, Inc. (ASPE) jointly with ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners X, LLC, CRANDELL KEITH, GILLIS STEVEN, NELSEN ROBERT | Purchase (P): 66,666 @ $15 · Conversion (C): 187,182 · Conversion (C): 298,258 · Conversion (C): 286,304 · Conversion (C): 295,490 · Conversion (C): 259,948 · +15 more | EDGAR |
| 2026-10-29 | 3 | Aspen Neuroscience, Inc. (ASPE) jointly with ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners X, LLC, CRANDELL KEITH, GILLIS STEVEN, NELSEN ROBERT | Holdings only — no transactions reported | EDGAR |
| 2026-10-19 | 4 | CITY THERAPEUTICS, INC. (CTY) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN | Conversion (C): 3,294,900 · Conversion (C): 5,482,309 · Conversion (C): 2,027,006 · Purchase (P): 170,000 @ $18 · Conversion (C): 3,000,000 (derivative) @ $0 · Conversion (C): 4,991,633 (derivative) @ $0 · +1 more | EDGAR |
| 2026-10-15 | 3 | CITY THERAPEUTICS, INC. (CTY) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN | Holdings only — no transactions reported | EDGAR |
| 2026-07-06 | 4 | Boundless Bio, Inc. (BOLD) jointly with CRANDELL KEITH, BYBEE CLINTON, NELSEN ROBERT, GILLIS STEVEN | Option exercise (M): 16,000 @ $1.03 · Sale (S): 16,000 @ $2.49 · Option exercise (M): 16,000 (derivative) @ $0 | EDGAR |
| 2026-07-06 | 4 | Scholar Rock Holding Corp (SRRK) | Sale (S): 2,105 @ $53.49 · Sale (S): 948 @ $54.28 | EDGAR |
| 2026-06-24 | 4 | Kardigan, Inc. (KARD) jointly with ARCH Venture Partners XIII, LLC, ARCH Venture Partners XIII, L.P., ARCH Venture Fund XIII, L.P., CRANDELL KEITH, NELSEN ROBERT, GILLIS STEVEN | Purchase (P): 1,250,000 @ $16 | EDGAR |
| 2026-06-22 | 4 | Kardigan, Inc. (KARD) jointly with ARCH Venture Partners XIII, LLC, ARCH Venture Partners XIII, L.P., ARCH Venture Fund XIII, L.P., CRANDELL KEITH, NELSEN ROBERT, GILLIS STEVEN | Conversion (C): 13,792,035 · Conversion (C): 5,148,587 (derivative) · Conversion (C): 1,204,000 (derivative) · Conversion (C): 2,306,401 (derivative) | EDGAR |
| 2026-06-08 | 4 | Scholar Rock Holding Corp (SRRK) | Grant/award (A): 6,839 @ $0 · Grant/award (A): 4,310 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Neumora Therapeutics, Inc. (NMRA) | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | Seaport Therapeutics, Inc. (SPTX) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, NELSEN ROBERT, GILLIS STEVEN | Conversion (C): 2,513,686 · Conversion (C): 2,681,265 · Purchase (P): 1,100,000 @ $18 · Conversion (C): 2,513,686 (derivative) @ $0 · Conversion (C): 2,681,265 (derivative) @ $0 | EDGAR |
| 2026-04-24 | 4 | Scholar Rock Holding Corp (SRRK) | Option exercise (M): 7,800 @ $26.78 · Option exercise (M): 28,000 @ $4.75 · Option exercise (M): 36,000 @ $9.11 · Option exercise (M): 18,000 @ $8.36 · Option exercise (M): 7,800 (derivative) @ $0 · Option exercise (M): 28,000 (derivative) @ $0 · +2 more | EDGAR |
| 2026-03-09 | 4 | Lyell Immunopharma, Inc. (LYEL) jointly with ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, CRANDELL KEITH, NELSEN ROBERT, GILLIS STEVEN, BERNS PAUL L, BYBEE CLINTON | Purchase (P): 488,090 @ $25.61 | EDGAR |
| 2025-11-13 | 4 | Metsera, Inc. (MTSR) | Disposition to issuer (D): 2,688 · Disposition to issuer (D): 17,070,904 · Disposition to issuer (D): 18,503,128 · Disposition to issuer (D): 7,523,682 · Disposition to issuer (D): 8,313,680 · Grant/award (A): 2,688 (derivative) · +2 more | EDGAR |
| 2025-10-29 | 4 | Neumora Therapeutics, Inc. (NMRA) | Purchase (P): 1,915,700 @ $2.61 | EDGAR |
| 2025-08-01 | 4 | Prime Medicine, Inc. (PRME) jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., CRANDELL KEITH, GILLIS STEVEN | Purchase (P): 3,030,300 @ $3.30 | EDGAR |
| 2025-06-23 | 4 | Boundless Bio, Inc. (BOLD) | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | Neumora Therapeutics, Inc. (NMRA) | Disposition to issuer (D): 46,455 (derivative) · Disposition to issuer (D): 28,571 (derivative) · Grant/award (A): 46,455 (derivative) · Grant/award (A): 28,571 (derivative) · Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | Scholar Rock Holding Corp (SRRK) | Sale (S): 1,000 @ $29.24 · Sale (S): 4,400 @ $29.83 | EDGAR |
| 2025-05-23 | 4 | Scholar Rock Holding Corp (SRRK) | Grant/award (A): 7,632 @ $0 · Grant/award (A): 9,206 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | Metsera, Inc. (MTSR) | Grant/award (A): 16,125 (derivative) @ $0 | EDGAR |
| 2025-02-18 | 4 | Neumora Therapeutics, Inc. (NMRA) | Disposition to issuer (D): 46,455 (derivative) · Disposition to issuer (D): 28,571 (derivative) · Grant/award (A): 46,455 (derivative) · Grant/award (A): 28,571 (derivative) | EDGAR |
| 2025-02-03 | 4 | Metsera, Inc. (MTSR) | Conversion (C): 16,006,949 · Purchase (P): 1,432,224 @ $18 · Conversion (C): 7,523,682 · Purchase (P): 789,998 @ $18 · Conversion (C): 19,933,333 (derivative) · Conversion (C): 15,000,000 (derivative) · +3 more | EDGAR |
| 2024-07-01 | 4 | Scholar Rock Holding Corp (SRRK) | Grant/award (A): 13,500 @ $0 · Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Neumora Therapeutics, Inc. (NMRA) | Grant/award (A): 20,100 @ $0 · Grant/award (A): 28,571 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Rapport Therapeutics, Inc. (RAPP) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, NELSEN ROBERT, GILLIS STEVEN | Conversion (C): 3,728,738 @ $0 · Conversion (C): 20,000,000 (derivative) @ $0 · Conversion (C): 11,924,138 (derivative) @ $0 | EDGAR |
| 2024-04-04 | 4 | Boundless Bio, Inc. (BOLD) | Conversion (C): 589,743 · Conversion (C): 787,545 · Conversion (C): 1,048,433 · Purchase (P): 66,667 @ $16 · Purchase (P): 133,333 @ $16 · Conversion (C): 424,908 (derivative) · +6 more | EDGAR |
| 2024-03-29 | 4 | Boundless Bio, Inc. (BOLD) | Grant/award (A): 26,438 (derivative) @ $0 | EDGAR |
| 2024-02-20 | 4 | Prime Medicine, Inc. (PRME) jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., CRANDELL KEITH, GILLIS STEVEN | Purchase (P): 3,200,000 @ $6.25 | EDGAR |
| 2024-02-12 | 4 | Sana Biotechnology, Inc. (SANA) jointly with CRANDELL KEITH, BYBEE CLINTON, GILLIS STEVEN | Purchase (P): 363,637 @ $5.50 · Purchase (P): 727,272 @ $5.50 · Purchase (P): 727,272 @ $5.50 | EDGAR |
| 2023-12-26 | 4 | Scholar Rock Holding Corp (SRRK) | Other (J): 291,906 @ $0 · Other (J): 5,339 @ $0 | EDGAR |
| 2023-12-12 | 4 | Neumora Therapeutics, Inc. (NMRA) | Other (J): 703,061 · Other (J): 1,176,593 · Other (J): 13,997 | EDGAR |
| 2023-11-15 | 4 | Neumora Therapeutics, Inc. (NMRA) | Purchase (P): 31,653 @ $11.75 · Purchase (P): 3,357 @ $11.98 | EDGAR |
| 2023-11-13 | 4 | Neumora Therapeutics, Inc. (NMRA) | Purchase (P): 69,127 @ $10.78 · Purchase (P): 23,124 @ $11.79 · Purchase (P): 31,079 @ $10.53 · Purchase (P): 11,844 @ $11.37 · Purchase (P): 5,431 @ $11.75 | EDGAR |
| 2023-11-07 | 4 | Neumora Therapeutics, Inc. (NMRA) | Purchase (P): 22,420 @ $11.38 · Purchase (P): 43,082 @ $11.55 · Purchase (P): 30,192 @ $11.50 | EDGAR |
| 2023-09-29 | 4 | Neumora Therapeutics, Inc. (NMRA) | Purchase (P): 16,841 @ $13.06 · Purchase (P): 25,110 @ $13.69 · Purchase (P): 34,560 @ $13.98 | EDGAR |
| 2023-09-27 | 4 | Neumora Therapeutics, Inc. (NMRA) | Purchase (P): 34,000 @ $11.73 · Purchase (P): 24,504 @ $12.31 | EDGAR |
| 2023-09-25 | 4 | Neumora Therapeutics, Inc. (NMRA) | Purchase (P): 40,000 @ $11.14 · Purchase (P): 30,773 @ $10.80 · Purchase (P): 29,967 @ $11.65 | EDGAR |
| 2023-09-20 | 4 | Neumora Therapeutics, Inc. (NMRA) | Conversion (C): 13,620 · Conversion (C): 684,167 · Conversion (C): 1,144,973 · Conversion (C): 6,895,021 · Conversion (C): 6,576,400 · Conversion (C): 2,124,143 · +7 more | EDGAR |
| 2023-09-18 | 4 | Neumora Therapeutics, Inc. (NMRA) | Grant/award (A): 46,455 (derivative) @ $0 | EDGAR |
| 2023-08-10 | 4 | DA32 Life Science Tech Acquisition Corp. (DALS) jointly with ARCH Venture Fund XI, L.P., ARCH Venture Partners XI, L.P., ARCH Venture Partners XI, LLC, NELSEN ROBERT, GILLIS STEVEN | Other (J): 1,600,000 | EDGAR |
| 2023-06-23 | 4 | Scholar Rock Holding Corp (SRRK) | Grant/award (A): 36,000 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2023-06-08 | 4 | Beam Therapeutics Inc. (BEAM) | Grant/award (A): 16,532 (derivative) @ $0 | EDGAR |
| 2022-10-26 | 4 | Prime Medicine, Inc. (PRME) jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., CRANDELL KEITH, GILLIS STEVEN | Conversion (C): 5,728,297 · Conversion (C): 5,728,297 · Purchase (P): 400,000 @ $17 · Purchase (P): 400,000 @ $17 · Conversion (C): 16,666,667 (derivative) @ $0 · Conversion (C): 16,666,664 (derivative) @ $0 · +2 more | EDGAR |
| 2022-09-02 | 4 | Beam Therapeutics Inc. (BEAM) | Grant/award (A): 10,391 (derivative) @ $0 | EDGAR |
| 2022-07-15 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2022-05-27 | 4 | Scholar Rock Holding Corp (SRRK) | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2021-08-09 | 4 | DA32 Life Science Tech Acquisition Corp. (DALS) jointly with ARCH Venture Fund XI, L.P., ARCH Venture Partners XI, L.P., ARCH Venture Partners XI, LLC, NELSEN ROBERT, GILLIS STEVEN | Other (J): 701,250 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-21 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1569248 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs